Indo-Bangla Pharmaceuticals Limited (DSE:IBP)

Market Cap	1.56B +0.8%
Revenue (ttm)	221.18M +150.4%
Net Income	-25.64M
EPS	-0.22
Shares Out	116.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.02 (0.11%)
Ex-Dividend Date	Dec 8, 2025

Volume	889,898
Average Volume	1,172,238
Open	13.80
Previous Close	13.70
Day's Range	13.30 - 13.80
52-Week Range	8.50 - 15.60
Beta	0.16
RSI	53.88
Earnings Date	Apr 30, 2026

About DSE:IBP

Indo-Bangla Pharmaceuticals Limited engages in the manufacture and sale of various medicines, medical preparations drugs, and chemicals in Bangladesh and internationally. The company’s principal products include Omeprazole, Esomeprazole, Dexamethasone, Domperidone, Metronidazole, Montelukast, Paracetamol, Sildenafil Citrate, and several other formulations. It markets its products in various forms, such as tablets, capsules. Indo-Bangla Pharmaceuticals Limited was founded in 1954 and is based in Dhaka, Bangladesh.

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 127
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: IBP

Financial Performance

In fiscal year 2025, DSE:IBP's revenue was 184.18 million, an increase of 4.27% compared to the previous year's 176.64 million. Losses were -36.83 million, -10.12% less than in 2024.